KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin (2019 - 2025)

Historic Net Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 36.66%.

  • Esperion Therapeutics' Net Margin rose 235900.0% to 36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.47%, marking a year-over-year decrease of 214500.0%. This contributed to the annual value of 1.46% for FY2024, which is 1829600.0% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Net Margin stood at 36.66%, which was up 235900.0% from 16.25% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Net Margin peaked at 42.29% during Q1 2024, and registered a low of 1140.0% during Q1 2021.
  • Over the past 5 years, Esperion Therapeutics' median Net Margin value was 178.06% (recorded in 2023), while the average stood at 230.12%.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 31326700bps in 2021, then crashed by -2462800bps in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Net Margin stood at 448.4% in 2021, then soared by 33bps to 302.06% in 2022, then skyrocketed by 41bps to 178.06% in 2023, then soared by 83bps to 30.16% in 2024, then decreased by -22bps to 36.66% in 2025.
  • Its Net Margin was 36.66% in Q3 2025, compared to 16.25% in Q2 2025 and 63.89% in Q1 2025.